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The purpose of this research is to investigate the shifting structure of pharmaceutical production in South Africa and 
examine the global and local factors that have contributed to this change. Generally, these factors have resulted in a 
decline in the number of pharmaceutical manufacturers in South Africa and in particular manufacturing operations 
owned by multinational companies. Simultaneously the global demand for generic medicines has increased due to their 
ability to improve access to affordable medicines. As a result, the supply of medicines in South Africa is being 
increasingly met by imported generic medicines and to a lesser extent locally manufactured generic medicines. These 
changes, together with a turbulent and sometimes uncertain regulatory environment, have led to interesting dynamics 
and changes within the structure of the pharmaceutical manufacturing industry in South Africa. 
 
 





In South Africa’s years of isolation from the international 
market prior to 1994, the local pharmaceutical industry was 
able to develop in terms of skills and infrastructure. Within 
this period, however, the provision of healthcare was not 
uniformly and equitably distributed amongst all members of 
the population (FRIDGE, 1999; Maloney & Segal, 2007). 
After the first democratic elections in 1994 the new 
government began to address this disparity by implementing 
policies and regulations to increase the affordability and 
accessibility of medicines for all sectors of the population. 
In essence this has been successful, as expenditure on 
medicines in South Africa has decreased (CMS, 2007; 
McIntyre & Thiede, 2007; Taylor, 2007). But the country 
has also seen a decline in the number of pharmaceutical 
production facilities in South Africa, as highlighted by 
large-scale industry reports (FRIDGE, 1999; Maloney & 
Segal, 2007).  
 
The purpose of this research is to explore the recent 
changing structure of production within the South African 
pharmaceutical industry. The research focuses on the recent 
trends in the global pharmaceutical industry, followed by an 





There has been a restructuring in the global pharmaceutical 
industry since the early 1990s (Cockburn, 2004; Heracleous 
& Murray, 2001; Scherer, 1993; Yeoh & Roth, 1999). This 
restructuring within pharmaceutical production and 
manufacturing has led towards the development of “centres 
of excellence,” where companies focus their production and 
manufacturing activities in a select number of countries. 
These countries are typically selected in terms of having the 
right combination of skills, a beneficial geographic location 
in the world market and the provision of government 
investment incentives to companies. This, coupled with the 
global trend towards mergers and acquisitions (M&A), has 
led to these companies becoming more cost effective and 
profitable. 
 
From the early 1970s, countries in the developing world, 
especially India and China, had focused mainly on generic 
drug manufacturing. These countries are now starting to 
form partnerships with R&D pharmaceutical companies in 
the developed world (Maloney & Segal, 2007). These 
partnerships are formed across the pharmaceutical value 
chain, for example R&D, drug production and clinical trials. 
This development has allowed companies from the 
developed world to cut costs as the developing countries can 
provide the companies with 
 
 skilled labour;  
 
 low-cost research facilities;  
 
 low-cost drug development sites, especially in terms of 
clinical trials;  
 




 low-cost distribution of drugs; and/or 
 
 low-cost sales and marketing (Maloney and Segal, 
2007). 
 
The South African pharmaceutical manufacturing industry 
in the late 1990s was well developed and, while operating 
within a relatively protected environment, it had become the 
most developed and largest pharmaceutical industry in 
Africa (FRIDGE, 1999). Despite this, however, 
globalisation and the restructuring of the pharmaceutical 
industry and in particular the increase in production of 
generic drugs in India had by the late 1990s resulted in a 
decline in employment within the local pharmaceutical 
manufacturing industry, which was about half of what it had 
been in the 1980s (FRIDGE, 1999). 
 
The industry’s global restructuring process towards “centres 
of excellence” has not benefited the South African 
pharmaceutical industry. This is evident in the steady 
decline in the number of multinational pharmaceutical 
manufacturing facilities operating in South Africa 
(FRIDGE, 1999; Maloney & Segal, 2007). In the five years 
prior to the FRIDGE Study (1999) conducted in 1999, over 
30 companies closed their manufacturing facilities. The 
main reasons for these closures included downsizing of 
operations, rationalisation, M&A, the increased tendency to 
import drugs and reasons relating to cost, which, in turn, 
were related to increased registration times.  
 
Maloney and Segal (2007) found that of the 16 multinational 
pharmaceutical companies operating in South Africa in 2007 
only ten still have manufacturing facilities, while the 
remaining six have contracted local companies to 
manufacture and pack their products. They further found 
that 35 pharmaceutical plants have closed down in South 
Africa since 1994, the majority being multinational R&D 
companies. This has led to a decrease in the number of 
people employed in the local pharmaceutical manufacturing 
industry. In 2000, 16,000 people were employed by this 
industry (this number was estimated at 18,000 in 1999 
(FRIDGE, 1999) and 18,000 in 2001 (Beare, 2001)) 
Employment in this industry had been reduced to 11,000 
employees by 2007 as a direct result of the closure of 
manufacturing facilities (Maloney & Segal, 2007). 
 
The FRIDGE Study (FRIDGE, 1999) found that owing to 
the opening of the South African economy the total market 
for wholly imported drugs was 30 per cent compared to 15 
per cent ten years prior to the study. Maloney and Segal 
(2007) also found that in 1998 the ratio of imported 
medicines ready for sale to locally produced medicines 
ready for sale was 8:1. By 2006 this ratio had increased to 
17:1. These ratios do not take into account the imported 
APIs and other inputs required for the local production of 
medicines. There has therefore been an increased use of 
imported medicines relative to locally produced medicines.  
 
There are various obstacles that the local pharmaceutical 




The FRIDGE Study (1999) found that in the late 1990s there 
was excess pharmaceutical manufacturing capacity in South 
Africa. At this stage it would have been possible for a new 
manufacturer to become established by merely contracting 
the production to existing manufacturers with spare 
capacity. The problem, however, was that the capital 
equipment and facilities in most cases were old and the 
technology was in some cases outdated. Machinery would 
have needed replacement to prevent the constant need for 
maintenance and therefore additional capital expenditure 
was required to attain a competitive level of output. These 
manufacturing plants were equipped with technology that 
was outdated and produced volumes that were too low to 
supply the international market. The running costs of these 
plants were therefore high relative to the volumes that they 
were producing at the time. In comparison with Asian 
manufacturing plants, the unit costs of the local factories 
were five times higher.  The lack of sufficient local capacity 
and economies of scale therefore led to a loss of 
competitiveness in terms of prices of locally produced 
medicines when compared to imports. 
 
South African drug policy 
 
Since 1994 the government has introduced significant shifts 
in government policies in an attempt to address inequalities 
in the pharmaceutical and healthcare sectors. These shifts 
have had some negative side effects, particularly within the 
pharmaceutical industry as it has affected the profitability of 
production (discussed below).  In September 1994 the 
Minister of Health appointed a Drug Policy Committee to 
establish the NDP with the aim of developing the following: 
 
 A pricing plan for drugs used in the public and private 
sectors of South Africa. 
 
 A plan for testing drugs and an evaluation of the 
effectiveness of drugs, based on epidemiological 
approaches in the South African context. 
 
 An essential drugs list and treatment guidelines for the 
health personnel for usage in the public sector. 
 
 Strategies for the increased usage of generic drugs. 
 
 A procurement and distribution plan for drugs in South 
Africa which effectively increases drug access in the 
rural areas. 
 
 A rationalisation of pharmaceutical services (DOH, 
1996).  
 
The pricing of pharmaceuticals in South Africa 
 
Since 1997 The Medicines and Related Substances Control 
Amendment Act 90 of 1997 and the regulations relating to a 
transparent pricing system for medicines and scheduled 
substances have been the government’s main legislative 
drives in making healthcare more affordable in South Africa 
(Taylor, 2007). The government’s Medicines Pricing 




Price (SEP). The pricing policies of the government have 
had the main purpose of regulating and lowering drug prices 
in order to make medicines more affordable. Maloney and 
Segal (2007) comment that most stakeholders believe that 
the policies lack transparency and economic feasibility, even 
though they accept the government’s goals of improving the 
access to and affordability of medicines.  
 
The public sector procurement of medicines  
 
The tender price preference system is a useful way for local 
manufacturers to secure demand for certain products that 
they supply to the public sector. This demand helps to utilise 
spare capacity and spread the overheads of a manufacturing 
facility over a greater number of units for the duration of the 
tender. Without a secure demand, the manufacturer would 
more than likely have to base its forecast of demand on 
more fickle market trends and other expenses, for example 
marketing costs, would also increase as a demand would 
have to be created in the market. The government’s 
procurement system of medicines for the public sector also 
raises concerns with regard to the effect that it has on the 
local pharmaceutical manufacturing industry. The 
procurement takes into consideration a ten-point system. Of 
these ten points four points are awarded for local content, 
four points for Black Economic Empowerment (BEE) 
compliance and the remaining two points for purchasing 
from small and medium enterprises (SMEs). Companies can 
then tender for providing high volumes of drugs to the 
public sector for three years in the case of ARVs and two 
years for any other drugs.  Maloney and Segal (2007) claim 
that importers of drugs can manipulate the government’s 
ten-point system for preferential procurement. These 
importers simply have to open up a small office with a small 
BEE compliant staff to attain a higher score. In contrast 
local manufacturing companies with a large staff 
complement would find it harder to be BEE compliant. 
 
Skills shortages and pharmaceuticals as a 
knowledge sector 
 
The pharmaceutical manufacturing industry requires a 
unique and specific set of skills, especially when one 
considers the range of skills required in the production, 
registration and marketing of medicines. Maloney and Segal 
(2007) assert that the government’s focus on primary 
healthcare has resulted in a diminished focus on tertiary 
healthcare as is evident in the decreased government 
funding of tertiary education in universities.  
 
Intellectual property rights (IPRs) 
 
Patented medicine producers seek to protect their 
intellectual property in order to set higher prices which 
enable the manufacturer to recover R&D costs. In an 
attempt to lower the costs of medicines in South Africa so as 
to improve the public’s access to medicines, the Medicines 
and Related Substances Control and Amendment Act of 
1997 has made provision for compulsory licensing, parallel 
importing and mandatory generic substitution. In mandatory 
generic substitution, South African pharmacists are required 
to dispense cheaper generic substitutes unless the doctor or 
patient insists on using the patented version of the same 
drug.  
 
Maloney and Segal (2007) conclude that: 
 
 the sector is essential in terms of providing healthcare 
and is therefore of strategic significance in order to 
secure the supply of medicines in South Africa, which 
has a rising incidence of infectious diseases; and 
 
 the sector does show growth potential to supply drugs 
for infectious diseases found in sub-Saharan Africa in 
partnership with other countries. 
 
South Africa needs to decide whether its drug market should 
be restricted to a local market or broadened out to an export 
market. The focus of the market then has to be decided and 
this could either be a focus on developing the entire 
pharmaceutical value chain or creating a competitive niche 
in strategic products and activities (Maloney and Segal, 
2007). 
 
These two dimensions are illustrated in Figure 1. The 
dimensions provide four main strategic areas that become 
possible when the two dimensions are combined. These 
main strategic areas are the North West (NW), the North 
East (NE), the South West (SW) and South East (SE) 
quadrant strategies. Up until recently, South Africa followed 
the SW quadrant strategy, where it attempted to substitute 
local production and activities across the value chain with 
imports. This strategy is uncompetitive and inefficient when 
confronted with global competition and produces very little 
for an export market. Maloney and Segal (2007) suggest that 
South Africa has the ability to develop sustainable 
competitive advantages in areas where it has demonstrated 
potential. In doing so, it can first meet the demand of the 
local and regional markets before expanding to export 
markets as its competitiveness increases in global terms. 
Interestingly since this 2007 study we have seen positive 









Figure 1: Proposed way forward for pharmaceuticals in South Africa 
Source: Maloney and Segal, 2007 
 
 
The economic liberalization of the 1990s resulted in the 
collapse of pharmaceutical industries in some locations and 
the rise of new competitors in others. Chittoor et al. (2009) 
discuss the emergence of third-world copycat producers 
which saw the Indian pharmaceutical industry come to the 
fore. Using longitudinal data on 206 Indian pharmaceutical 
firms from 1995-2004 they find that firms’ access to 
international technological and financial resources have 
enabled product market internationalization. They maintain 
that the exogenous shocks, in the form of comprehensive 
institutional reforms that changed the global rules of the 
game affected the players and changed their dynamic 
capabilities. They illustrate that Indian firms took the 
international offensive strategy by engaging in an iterative 
process of resource and product market reconfiguration. In 
contrast to South Africa’s reaction to these global 
developments whereby it tried to protect the local industry 
through barriers, the Indians enabled better export 
performance by facilitating the acquisition of international 
resources (including technology) to complement indigenous 
advantages. Likewise Athreye, Kale and Ramani (2009) 
shows that radical regulatory changes such as the Indian 
Patent Act of 1970, the New Industrial Policy of 1991 and 
the signing of TRIPS in 1995 served to open up economic 
opportunities for those companies and countries that 
developed dynamic firm capabilities. While much of the 
discussion below on South Africa will point to the passive 
response of South African pharmaceutical companies to 
these international developments, the global evidence is that 
those that have thrived seized the opportunities presented by 
these flattening economic forces. Athreye et al. (2009) argue 
that dynamic capabilities evolve over time due to 
endogenous market changes and exogenous shocks. These 
disruptions provide opportunity for renewal and the 
redeployment of existing capabilities. They find that Indian 
firms exploited these new opportunities by i) entering into 
the generic markets of developed countries, ii) collaborating 
with Western multinationals on different segments of the 
sequential process of new drug commercialization, and iii) 





This research was exploratory in nature and a qualitative 
approach was used to investigate the responses to the 
research questions (see Appendix A for research 
instrument), which were asked in interviews with 
stakeholders within the pharmaceutical industry. The 
targeted population includes all the stakeholders within the 
South African pharmaceutical industry that have a direct 
connection with pharmaceutical production or have the 
ability to influence the nature or structure of pharmaceutical 
production in South Africa.  A sample of 13 individuals was 
selected to take part in the interviews all of which were in 
senior management positions (see Appendix B for list of 
respondents). Interviews were conducted face-to-face to 
allow for probing and further discussion of the research 
questions. To reduce the biased nature of the sample 
individuals from different areas of the industry were 
selected. Three individuals from MNCs involved in local 
manufacturing were interviewed; one of these individuals 
represented a large MNC specialising in generic medicines. 
Three individuals from each of the three largest local 
manufacturers were interviewed as well as two individuals 
from smaller local manufacturers, one of which is involved 
exclusively in contract manufacturing. One respondent was 
selected from the DOH and more specifically from the 
MCC, and another from the DTI in order to gain the 
government’s perspective on the research topic. Two 
individuals were selected from industry organisations and, 
lastly, one individual was selected from a professional 
 Export everything 
NW Quadrant Strategy: 
Attempt to become like 
China or India 
NE Quadrant Strategy: 
Attempt to be a global 
leader in production and/or 
development of niche drug 
areas 
SW Quadrant Strategy: 
Attempt import 
substitution 
 SE Quadrant Strategy: 
Attempt strategic self-



















organisation that represents pharmacists in the 
pharmaceutical industry. The selected individuals all had 
either direct involvement or intimate knowledge of the local 
pharmaceutical production industry.  
 
Presentation and discussion of results  
 
The global pharmaceutical industry’s impact on the 
changing structure of South African pharmaceutical 
production 
 
All of the respondents indicated that the two largest global 
factors that influenced local pharmaceutical production have 
been the consolidation of global manufacturing activities of 
MNCs and the increased global usage of generic medicines. 
 
Consolidation of global pharmaceutical production 
 
All the respondents agreed that the single biggest global 
factor that has influenced pharmaceutical production by both 
South African companies and MNCs in South Africa has 
been the events that have taken place within global 
pharmaceutical manufacturing in recent decades. In the last 
15 to 20 years global pharmaceutical manufacturing by 
MNCs has undergone a transition, whereby MNCs have 
consolidated their manufacturing facilities globally to create 
centres of excellence. These centres are typically large 
consolidated manufacturing facilities that often produce 
specific drugs or drug categories for geographic regions, 
particular markets and in some cases for the entire global 
market of an MNC. Previous to this period in the late 1980s 
and early 1990s MNCs often had many manufacturing 
facilities globally in countries where they had marketing, 
sales and distribution activities.  
 
The main drive towards establishing these centres of 
excellence has been to achieve two objectives 
simultaneously. First, economies of scale can be achieved 
when large volumes of a limited variety of drugs are 
produced in one facility. All companies and industry 
organisations interviewed were in agreement that this drive 
to lower costs and improve production efficiencies has also 
been motivated by the MNCs’ need to remain viable and 
sustainable in markets. Secondly, by producing the total 
supply of a drug for the global market in one facility a 
manufacturer would also be able to maintain and assure 
uniform high quality standards of produced drugs. A 
respondent from a large multinational generic company 
commented that the emphasis on high drug quality standards 
has become both a requirement and an expectation globally, 
regardless of whether the drug is a new innovative drug or a 
generic drug.   
 
Five of the respondents argued that merger and acquisition 
(M&A) activity amongst MNCs further resulted in the 
establishment of centres of excellence. The main reason for 
the M&A activity in this industry has been to gain synergies 
in R&D capabilities that result in the delivery of new 
innovative drugs that can be protected by a patent. Typically 
with this trend the manufacturing functions of the merged 
companies would also be consolidated and merged in order 
to achieve manufacturing synergies and uniform quality 
controls over the production of a larger variety of drugs.  
 
Half of the people interviewed, and in particular those 
affiliated to large MNCs, agreed that the centres of 
excellence are mostly established in countries or regions that 
fulfil certain criteria. These criteria most often include cost 
advantages such as tax incentives and other incentives 
provided by the governments of these countries in order to 
attract foreign direct investment (FDI). In addition to this, 
these countries often have a large skills base as a result of 
high education standards coupled with a relatively low cost 
of skilled and semi-skilled labour. Countries like Puerto 
Rico, Brazil, Singapore, China and most notably India were 
given as examples of nations that provided the MNCs with 
attractive incentives for the establishment of these centres of 
excellence. A respondent from a large local generic 
company commented that the MNCs assess the political 
climate, infrastructure and economic stability of these 
countries prior to investing in regional manufacturing 
facilities in order to minimise the risks of such large 
investments. 
 
Individuals from both industry organisations and a 
government department that were interviewed emphasised 
that at the time of these developments the South African 
government had perhaps not provided global MNCs with 
sufficient incentives to invest in the expansion of their 
existing operations or in the establishment of new large 
manufacturing facilities in South Africa.  
 
Global generic medicine demand 
 
The majority of the people interviewed stated that in the last 
20 years there has been an increase in the production of 
generic drugs predominantly in developing countries in Asia 
and most notably in India and China. This general shift of 
total global drug production volumes from the west to the 
east has been driven by the rising demand for generic 
medicines in developing countries. These developing 
countries previously had poor access to affordable 
medicines. Often the governments of developing countries 
have provided their local pharmaceutical industry with 
protection from competing with imported drugs by 
establishing high import tariffs for imported medicines. 
These governments also often provide incentives, e.g. tax 
incentives when the manufacturers are able to export 
medicines.  
 
This trend has enabled the pharmaceutical manufacturing 
capability and capacity in a country like India to advance 
and grow. A representative from the DTI mentioned that up 
until fairly recently India used to be the seventh-largest 
producer of medicines globally. With the tremendous 
growth experienced in the Indian pharmaceutical industry, 
India has, in the last four years, become the world’s second-
largest producer of medicines and has a pharmaceutical 
production volume output equivalent to Germany’s. The 
capability of the Indian pharmaceutical industry has resulted 
in its ability to attract contract-manufacturing opportunities 
from large MNCs that have outsourced their production 
activities in order to focus on R&D. An interviewee from a 
large local generic medicine manufacturer claimed that India 
has the largest number of FDA-approved production 




local manufacturer and importer, become the “pharmacy to 
the world”.  
 
With an increase in the usage of generic medicines globally 
the demand for generic medicines has also increased in 
South Africa. Post 1994 and especially after the 
establishment of the South African government’s NDP in 
1996 an emphasis has been placed on increasing the general 
population’s access to medicines. An opportunity has 
therefore been created for both large and small local 
manufacturers of generic medicines and in particular those 
that have already been manufacturing generic medicines. 
Importers of finished generic products, APIs and raw 
materials into South Africa have also benefited from this 
increase in demand. A respondent from an MNC based 
locally stated that this has created an opportunity for local 
importers to import finished generic products, APIs and raw 
materials predominantly from India, as local pharmaceutical 
manufacturers do not possess the economies of scale to meet 
the total demand for generic medicines locally. The 
importation of cheaper generic medicines has increased the 
competition within the local industry, which has placed a 
greater emphasis on low cost and high volume production 
locally.  
 
Price controls and TRIPS 
 
It is evident from the literature review that price controls on 
medicines have had an impact on the production of 
medicines globally (see Danzon, Mulcahy & Towse, 2011). 
The effect of these price controls, however, is unique to the 
government in each country that establishes a system of 
price controls. Most price controls implemented globally 
have been to reduce medicine prices and this has also 
resulted in the increased demand and usage of generic 
medicines in both developed and developing countries.  
 
IPR issues have had an effect on both global and local 
pharmaceutical manufacturing. The Medicines and Related 
Substances Act 90 of 1997 has made provision for both 
parallel importation and compulsory licensing. Respondents 
noted that the legal provision for parallel importation and 
compulsory licensing poses a minor risk for MNCs wishing 
to invest in South Africa. The risk exists that the IPRs of 
MNCs on a patented medicine could be threatened in the 
event of a national health crisis like HIV/AIDS that requires 
large-scale treatment with that medicine. Despite the 
perceived risks, all the respondents agreed that intellectual 
property issues had little effect on the decisions made by 
MNCs to withdraw their manufacturing presence from 
South Africa.  
 
Local factors impacting on the changing structure of 
South African pharmaceutical production  
 
Respondents noted that for the most part, the environment of 
the local pharmaceutical production industry appears to be 
influenced by two opposing objectives. The first objective is 
the South African government’s objective of ensuring a 
continuous and sustainable supply of affordable quality 
medicines to meet the healthcare needs of the entire 
population. The industry’s objective, on the other hand, is to 
remain sustainable and profitable in order to reward its 
shareholders. In doing so, the industry has to find ways to 
operate successfully within the confines of the government’s 
legislation and policies by responding collectively in order 
to influence new legislation and policies. Both the 
government and the industry therefore need to be able to 
work together harmoniously in order to achieve these 
interdependent objectives.  
 
All the respondents stated both directly and indirectly that 
the largest factor to influence the local manufacturing 
industry was the government’s responsibility in increasing 
the entire South African population’s access to affordable 
quality medicines. This responsibility has further been given 
a higher priority with the growing prevalence of diseases 
such as HIV/AIDS and TB. The DOH has increased access 
to affordable medicines by introducing price controls in the 
form of the SEP and by providing for parallel importation 
and compulsory licensing.  
 
Strategic vision of large local manufacturers 
 
From the pharmaceutical manufacturers’ point of view the 
greatest change that has occurred is the response of the 
largest local generic medicine producers to the decline in 
manufacturing presence locally. With a growing market for 
affordable medicines globally and, the South African 
government’s increased drive to improve access to 
medicines, opportunities still exist for local pharmaceutical 
manufacturers, particularly for the three or four largest 
companies manufacturing generic medicines. One 
respondent from an MNC with a local manufacturing 
presence emphatically stated that the market for generic 
medicines in South Africa would: “grow and grow and grow 
and grow and grow”. All of the manufacturers that were 
interviewed agreed that this response to external global 
factors and internal legislative parameters and objectives has 
resulted in the largest change in recent pharmaceutical 
production. South Africa’s largest generic drug producer 
appears to have been the most innovative in capturing local 
opportunities, firstly, and then international opportunities, 
thereby taking the lead within the local pharmaceutical 
manufacturing industry. 
 
With the government’s legal provision for compulsory 
licensing, the largest generic producer was the first to 
negotiate an alternative solution to overcome the 
government’s intention to issue compulsory licences to 
provide ARVs in the treatment of HIV/AIDS. A senior 
executive from this company who was interviewed 
commented that in the late 1990s the company realised that 
it needed to achieve economies of scale in order to fund the 
investments required in its production facilities to upgrade 
them from local MCC standards to gain international 
accreditation from organisations such as the WHO and the 
FDA. This was undertaken in order to exploit future export 
markets as part of an expansion strategy. At the same time 
there was an increase in global funding available for the 
manufacturing of ARVs and this included funding from the 
Clinton Foundation and PEPFAR shortly thereafter. 
Together with the available funding there was a large market 
with a large demand for ARVs but no local manufacturer 
with the capacity to meet this demand. This company had 




(GSK), Bristol-Myers Squibb (BMS), Eli Lilly and Gilead 
Sciences to gain voluntary licences to manufacture ARVs. 
These voluntary licences included technology transfers from 
the MNCs and enabled the large local manufacturer to 
increase its economies of scale. The manufacturer also 
became the first manufacturer globally to gain FDA 
approval to manufacture generic ARVs. These successes 
have enabled the company to reinvest in its manufacturing 
capabilities, which has resulted in gaining FDA approval for 
a sterile manufacturing plant, which has enabled the 
company to export large volumes of eye drops to the U.S. 
The respondent commented that the company’s success had 
been achieved through vision and fortitude. This vision has 
led to this company to attain 11 manufacturing plants 
locally, export products to 100 markets globally and attain a 
physical presence in the U.K., U.S., Latin America, East and 
West Africa, Australia, the Middle East, Asia, and shortly in 
South East Asia (at the time of the interview in 2009). The 
second-biggest global MNC, GSK, now has a 19% stake in 
the business and the company is licensing products to GSK 
and manufacturing branded products for Eli Lilly and Gilead 
Sciences. At the time of the interview the company was 
between the twelfth- and fourteenth-largest generic 
medicines manufacturer globally.  
 
Capacity constraints of the MCC 
 
Five of the respondents indicated that the inefficiency of the 
MCC has resulted in delays in the registration process of 
new patented and generic medicines and delays in other 
administrative functions performed by the MCC. With such 
delays companies could potentially lose market share to 
other suppliers of therapeutically similar medicines in the 
market. The respondent from the MCC explained that the 
MCC has experienced capacity constraints because it is 
understaffed. In 1998 it employed 100 staff members and 
received about 300 applications for the registration of new 
medicines. Currently it employs 107 staff members and 
receives about 1,700 applications per annum. This, 
according to the respondent, is the main reason for the 
administrative backlog of the MCC and for the local 
registration of medicines being four times longer than the 
global average. The MCC, according the respondent, is 
moving towards becoming a statutory body as an 
independent organisation, which would enable it to 
negotiate its own salary levels and staff requirements. 
Previously the MCC was forced to work within the 
boundaries of the DOH, where posts for specific technical 
requirements were restricted to a limited number of people.  
 
A respondent from a local manufacturer and importer of 
generic medicines commented that the inefficiency of the 
MCC has inadvertently protected the local industry. Had the 
MCC had been more efficient, in this respondent’s opinion, 
a greater number of competing Indian importers would have 
registered many more products locally, resulting in greater 
competition on the basis of price. If the MCC’s efficiency 
were therefore to be improved, the government would have 
to find other means to protect local players from competing 
with cheaper imported products. The greatest impact on 
local production from the point of view of the MCC came 
about with the amendment to the Medicines and Related 
Substances Control Amendment Act 90 of 1997 which was 
promulgated in 2003. In particular section 22C of the Act, 
which has granted the MCC the authorisation to issue 
manufacturing licences to local manufacturing companies 
that comply with the PIC/S and the 2009 GMP standards. 
The regulatory authority also now has the authority to 
withdraw a licence should a local manufacturing company 
not comply with these current standards. Prior to this the 
MCC had no real authority to close down non-compliant 
facilities. Two of the respondents indicated that the manner 
in which the MCC has enforced compliance with the PIC/S 
and the 2009 GMP standards has been problematic. A 
respondent from a global generics producer that relies on the 
production capacity of smaller local contract manufacturers 
said that the requirements to attain a manufacturing licence 
are often below the requirements of the company’s global 
production standards. This makes sourcing local companies 
to conduct contract manufacturing problematic, as their 
standards are often too low. This respondent suggested that 
a greater collaborative approach between manufacturers and 
the MCC must be adopted in order to ensure that 
manufacturers become compliant with current local 
manufacturing standards. In doing so, this respondent felt 
that manufacturers that comply with standards must be 
provided with incentives or stand a greater chance to 
provide medicines for government tenders.  
 
Single exit pricing (SEP) 
 
The government introduced the SEP system in 2004 in order 
to increase the access to affordable medicines and reduce 
healthcare costs in general. The respondent from the DTI 
made the observation that South Africa used to be the only 
country outside the U.S. that did not have some form of 
price control over medicines. Another respondent from an 
industry organisation commented that because of this South 
Africa used to be an attractive market for MNCs. All the 
respondents commented that price controls have had the 
effect of reducing the profit margins on medicines that are 
sold locally. This has resulted in increased pressure on 
suppliers to increase their economies of scale in order to 
reduce the cost per unit produced. One small local 
manufacturer commented that the reduction in prices could 
also result in local supply issues, where some companies 
stop the production of certain products, as it no longer 
remains economically viable to produce them locally. Two 
respondents from local manufacturers of generic medicines 
mentioned that the price controls also force local companies 
to source certain finished products from other markets like 
India. In some cases one of these local companies has also 
moved some of its manufacturing facilities to India in order 
to reduce costs to compete locally on price.  
 
Two of the smaller suppliers of medicines who rely on 
contract manufacturing claimed that the SEP determined for 
the year is not predictable and this makes forecasting and 
budgeting activities difficult. It is therefore difficult to 
forecast what the costs of the companies’ other activities, 
like marketing, should be in order to still be able to realise a 
profit. Respondents from two MNCs and an industry 
organisation expressed the fear that the benchmark pricing 
regulations that are currently being considered by the 
government could further reduce the viability of producing 




local price of medicines would be determined by lowest 
price at which these products are sold in a grouping of four 
other countries. The outcome and implementation of this 
proposal is, however, not certain at this stage and pricing is 
currently only determined by the SEP system. A respondent 
from an industry organisation commented that this 
uncertainty over the implementation of benchmark pricing 
further contributes to a general uncertain investment 
environment.   
 
The government’s intention of establishing a unified, 
equitable and integrated national health insurance system in 
the form of the proposed National Health Insurance (NHI) 
scheme would in theory create a very large market for 
medicines in South Africa. Five of the respondents raised 
concerns about the NHI and what implications it might 
have, but as the implementation of such a system is not clear 
at this stage they could only speculate. Two respondents 
from MNCs and two from industry organisations predicted 
that under such a system the demand for generic medicines 
within South Africa could increase drastically. Concerns 
were raised about the influence and downward pressures this 
would have on medicine prices. The respondents speculated 
that under these conditions the market would initially be 
very competitive until the prices dropped to such an extent 
that the local manufacturers would withdraw their products 
from the market. The government would then have to import 
cheaper medicines to meet the local demand and this might 




A respondent from one of the largest local manufacturers 
commented: “The intense regulatory period that the industry 
has faced in the last ten to 15 years has been unabated and 
every time you think you pass a regulatory hurdle for 
example benchmark pricing or NHI, another arises. The 
industry has been characterised by regulatory uncertainty 
and unpredictability.” The respondents’ reactions to the 
government’s policies were for the most part not particularly 
favourable. They pointed out that although the DTI has 
targeted this sector as a priority, there are conflicting signals 
being given from other departments particularly from the 
DOH. 
 
DTI’s National Industrial Policy Framework (NIPF) and 
Industrial Policy Action Plan (IPAP) include the 
pharmaceutical industry among the “lead sectors” targeted 
for economic intervention. The action plan focuses on the 
designation of the production of ARV’s as a “strategic 
industry”, and on the expanding local capabilities / increase 
domestic production of ARV’s through leveraging the ARV 
tender. Over R8 billion went out on state tender in terms of 
drug procurement during 2009 and 2010 alone. Also about 
R900 million in DTI incentives were given to 
pharmaceutical projects under various DTI programmes 
between 2003 and 2008. Furthermore, the pharmaceutical 
sector is amongst “priority sectors” in the new Enterprise 
Investment Programme – Manufacturing (EIP – MIP), 
which is a tax-free cash grant to upgrade small and medium 
pharmaceutical plants to cGMP standards. The overall 
objectives of the programme are to increase the 
competitiveness of manufacturing sectors by promoting / 
incentivising investment in advanced technologies (new 
products), equipment and skills. 
 
Some local manufacturers have benefited from the 
incentives that have been provided to local manufacturers, 
but as one respondent from an industry organisation 
commented the provision of these incentives mostly favours 
large generic medicine producers with a manufacturing 
presence. This could result in a declining demand for 
innovative-patented medicines provided by MNCs. A 
respondent from a large generic medicine producer also 
commented that the Indian pharmaceutical industry enjoys 
many more incentives, such as tax breaks and defensive 
import tariffs against importing medicines into India. This 
generally puts local manufacturers at a disadvantage against 
importers, who are often able to compete for the public 
procurement programmes based on the fact that their 




All of the respondents were in agreement that importing 
APIs, raw materials and in some cases processing equipment 
has had a negative impact on the cost of producing 
medicines locally. Risks are also evident when APIs are in 
short supply, causing a shortage of a locally produced 
medicine. One respondent also noted that large suppliers 
often focus on supplying larger markets like the U.S. and 
Europe first, which could further lead to a local shortage. A 
respondent from a government department claimed that 
99 per cent of the APIs and raw materials used in locally 
produced formulations are imported. This has an additional 
negative impact on the local trade balance, especially when 
one views the high costs of the APIs used for ARVs. Three 
respondents estimated that APIs in general contribute about 
60 to 80 per cent of the cost of medicines and that, therefore, 
if these APIs were produced locally this would improve the 
trade deficit. The DTI is meeting regularly with the top 
producers of ARV APIs to encourage them to produce these 
APIs in South Africa. The willingness of these producers to 
invest in an API production facility locally appears to 
depend on the type of incentives that the government is 
willing to provide them with for establishing an API plant in 
South Africa. 
 
Respondents from an MNC and two industry organisations 
doubted the viability of such a venture because to justify the 
expense of establishing an API plant the volumes produced 
would have to be larger than the local demand in order to 
make such a facility economically viable. It therefore seems 
doubtful that any manufacturer would be willing to invest in 
such an endeavour. One industry organisation after 
analysing this proposition found that sourcing from a local 
API producer would not be viable if the price of that API on 
the global market was less than the local suppliers’ price. 
Two respondents noted that it would be strategically 
important for South Africa to produce a limited range of 
APIs required for diseases that are prevalent regionally and 
in the rest of Africa. South Africa could then exploit the 
markets within Africa with locally produced APIs and 
medicines and even become a centre of excellence for 
products demanded in Africa. Starting such an industry 




industry that would supply intermediate chemicals used in 
the production of APIs. These industries could further 
provide opportunities to build skills locally and provide 
opportunities for innovation within the local pharmaceutical 
sector. 
 
Local skills shortage 
 
All the respondents saw the local skills shortage within the 
pharmaceutical manufacturing industry as being 
problematic. The skills that appear to be in the shortest 
supply are the skills of pharmacists within the 
manufacturing industry. A third of the respondents 
emphasised that South African pharmacists at university 
level are primarily trained to become community 
pharmacists and as a result of this are fairly ill equipped to 
operate affectively in a pharmaceutical production 
environment.  
 
The largest local manufacturer noted that its in-house skills 
had lagged behind its manufacturing ability and that this had 
been corrected by bringing in skilled people from Europe 
and India to act as trainers within local facilities to facilitate 
in addressing this lag. The second-largest local manufacturer 
commented that it had been necessary to import skills to 
facilitate local in-house skills transfer. Another respondent 
noted that the industry should find ways of providing 
pharmacist interns with opportunities to gain industrial 
experience and also find ways of increasing the skills of 
other technical people within the facilities to reduce the 
dependence of pharmacists at all the levels of 
pharmaceutical production.  
 
Numerous other issues were raised by respondents, such as 
 
 impacts that BEE has on the employment of persons 
who lack sufficient skills and require an opportunity to 
gain skills, which impacts on costs; 
 
  high costs of employing professional skills compared 
to India; 
 
 the demise of the Pharmaceutical Production 
Technology course that offered pharmaceutical 
technicians training within a production environment 
(this course was previously administered by the 
Pharmaceutical Manufacturers Association (PMA)); 
 
 the reduced number of people entering the pharmacy 
profession; 
 
 the important contribution that the pharmaceutical 
industry makes to skills within South Africa; and 
 
 the generally high cost of skilled and semi-skilled 
labour within the industry. 
 
Implications of the changing structure of the local 
pharmaceutical industry and the industry response 
 
On a broad level the local pharmaceutical production 
industry’s structure has changed from being dominated 
mostly by MNCs and a few local players to becoming an 
industry with a few large local generic medicine companies. 
With the gradual closure of manufacturing facilities by large 
MNCs and the government’s emphasis on increasing access 
to cheaper generic medicines, the biggest change has come 
about by the largest generic medicine producers attempting 
to find value within the local market. The constraints of 
government legislations and policies and the general 
regulation environment have provided the largest local 
manufacturers with hurdles that have been overcome 
through innovation and a determination to remain viable. 
The potentials of a large local market and the prospects of 
unexploited export markets have created further 
opportunities for growth and sustainability for local 
manufacturers and local contract manufacturing. The growth 
of the local industry has become of strategic importance to 
the government, as seen by the IPAP, with its emphasis on 
ensuring the security of the supply of medicines locally and 
on stimulating the economy in order to reduce the trade 
imbalance. It has become clear that an improvement in the 
cooperation and communication between the government 
and the industry is of strategic importance to both parties in 
achieving their objectives.  
 
Opportunities within the transformed industry 
 
As mentioned previously, with the closure of the MNCs’ 
production facilities, the largest local companies 
experienced growth. This growth was facilitated by the 
manufacturing of ARVs through voluntary licensing 
agreements which enabled technology transfers, the 
achieving of economies of scale and the gaining of 
international accreditation, in particular FDA approval of 
the two largest manufacturers’ facilities. This situation has 
also resulted in local manufacturers with the potential to 
exploit export markets in developed countries. One 
respondent noted that despite the higher cost of local 
production it is in some cases still lower than the cost in 
developed countries like the U.S. and countries in Europe. 
In addition to this, South Africa has good infrastructure and 
a sound regulatory environment, with an emphasis on 
quality compared to other countries where low-cost 
medicines are produced. 
 
Part of the intention of the IPAP was to place an emphasis 
on preferential procurement from local manufacturers, 
especially with the provision of ARVs to the public sector. 
A respondent from a local generic medicine producer and 
importer commented that the price of one particular ARV 
supplied to the state tender is still nine times more expensive 
than the price at which Indian companies sell the drug to 
other African countries. In this respondent’s opinion 
sourcing medicines locally is not necessarily going to 
increase the access to medicines in the long term. 
Furthermore it will not be viable to protect local 
pharmaceutical manufacturing and the employment within 
this industry at the cost of denying about 50 million people 




The respondent from the largest local manufacturer stated 
that sourcing from importers may be cheaper but by denying 
the economic viability of local producers the government, in 
addition to negatively affecting the balance of payments 
through increased importation, could lose in terms of tax 
collection and the local producers’ ability to improve 
employment and skills locally. The purpose of the IPAP in 
this respondent’s opinion is to allow South African 
companies to compete on equal terms with other countries 
like India, which are primarily able to be low-cost suppliers 
owing to the protection they enjoy from their government. A 
local manufacturer, however, noted that providing 
incentives for local manufacturers might present 
opportunities that are attractive for Indian or Chinese 
companies to manufacture in South Africa. If the 
government made it a prerequisite for interested foreign 
manufacturers to manufacture in South Africa and to have 
an empowered company when supplying drugs to the public 
sector, this would provide fair competition to other players 
within the local industry.  
 
Almost all the respondents mentioned that the local industry 
had not yet been able to exploit the growing market for 
medicines in Africa, and that South Africa has the 
infrastructure and a good regulatory environment for 
supplying quality medicines to Africa. Two respondents 
commented that South Africa should become a regional hub 
for pharmaceuticals where medicines required in Africa 
should be produced in Africa. In support of this, another 
local manufacturer suggested that, in order to assist the 
introduction of products into the rest of Africa there should 
be an attempt at establishing a regional regulatory authority.  
 
Co-operation within the industry and with government 
departments 
 
All the respondents that were interviewed commented on the 
increasing trend in which local companies enter into 
marketing, licensing or manufacturing agreements with 
larger MNCs. The motivation behind this trend appears to 
be supported by a new confidence that the large global 
pharmaceutical corporations have in local manufacturing 
capabilities. For the largest local manufacturer, this has 
resulted in being 19 per cent owned by GSK, which appears 
to be a mutually beneficial arrangement for both parties to 
extend product lines and exploit global markets. The 
second-largest manufacturer, according to a respondent, is 
now also entering into marketing agreements with another 
large MNC, which apart from recognising the 
manufacturer’s production capabilities also realises the 
value of this manufacturer’s exclusive distribution network 
within South Africa and regionally. All the other companies 
that were interviewed are either MNCs that have contracted 
work out to local companies or are local manufacturers that 
conduct contract manufacturing for MNCs. In addition to 
this, there are also MNCs that still have manufacturing 
presence and have spare capacity to manufacture products 
for other MNCs that no longer have facilities to manufacture 
locally marketed products. 
 
This represents another important change within the local 
pharmaceutical industry, as very few companies now 
operate in complete isolation from other companies. This 
trend could result in greater co-operation within the 
manufacturing industry and the creation of new smaller 
manufacturing companies and perhaps a regional 
manufacturing hub. Respondents from industry 
organisations also highlighted possible further trends that 
may occur within the manufacturing industry. One of these 
trends is the possible backward integration of large medicine 
retailers into pharmaceutical production in order to 
manufacture their own brands and to save on the costs of 
sourcing from contract manufacturers. Another possibility is 
that the government may itself establish state-owned 
pharmaceutical manufacturing facilities in order to achieve 
economies of scale with a large market. The establishment 
of Public Private Partnerships (PPPs) between local 
companies and the government has also been mentioned as a 
possible solution for reducing prices and increasing access 
to medicines predominantly in the public sector. 
 
Almost all the respondents agreed that the industry, through 
its various industry organisations, is able to respond to and 
communicate collectively with government departments. In 
many cases the nature of the interactions between the 
industry and government seems to be influenced by distrust 
from both parties, which fail to create a constructive forum 
to address important issues and to understand the other 
party’s concerns, objectives and points of view. The 
majority of the respondents also commented on the lack of 
cohesion between the various government departments. A 
respondent from a government department specifically 
mentioned that there is as yet no clear industrial policy for 
the pharmaceutical industry and that when the DTI had 
started to establish a policy in 1999 the DOH and the 
Treasury were not forthcoming or willing to adopt a strategy 
as these stakeholders had their own interests. This 
respondent claimed that: “The DTI tries to balance the 
points of view of the DOH, Treasury and the pharmaceutical 
industry. All these stakeholders have different interests and 
it is essential that they agree on the same strategy.” 
 
The future of pharmaceutical production in South 
Africa 
 
Of the 12 respondents, all apart from two believed that the 
future holds many opportunities for local pharmaceutical 
production and in particular the production of generic 
medicines. By contrast, one respondent from a government 
department indicated that if there is no intervention from 
government in the form of a strategic plan or comprehensive 
industrial policy there will be a complete decline in local 
pharmaceutical production by the year 2020. Another 
respondent from a large local producer and importer of 
generic medicines commented that increasing access to 
medicines by importing less expensive generic medicines is 
of greater importance than creating capacity in local 
manufacturing facilities.  
 
The remaining ten respondents raised several issues that 
could determine the future success of local pharmaceutical 
manufacturing. In general, the quality of produced 
medicines appears to be recognised as one of the main 
characteristics that will determine the acceptance of locally 
produced medicines in the local market and in export 




capitalising existing facilities in order to meet the local and 
where applicable international regulatory requirements. The 
MCC in particular has noted that the upgrade in local 
facilities is indicative of growth and expansion.  
 
The emphasis on the provision of cheaper generic medicines 
and essential drugs locally appears to be the main threat to 
the market share of patented innovative medicines. Issues 
regarding the protection of intellectual property and price 
controls pose further threats not just to manufacturing 
presence but to the marketing of patented medicines in 
general, especially in the environment of the proposed NHI. 
The MNCs are, however, in consultation with the 
government to emphasise the important role that innovative 
or patented medicines can play locally. These medicines are 
often therapeutically superior to older generic medicines and 
have a high benefit to cost ratio which could reduce other 
healthcare needs such as hospitalisation. Within the context 
of the NHI there may also be certain medicines that are 
required for obscure diseases that are only supplied by 
companies providing innovative-patented medicines. In 
addition to this, the patented medicines on the local market 
are able to become the generic medicines of the future once 
the patent has expired. Despite this, MNCs are beginning to 
partner with local companies to manufacture products that 
are unique to the local market and are not produced 
elsewhere. At another level MNCs are approaching local 
companies to manufacture for global markets.  
 
In general, the next step in the industry’s growth appears to 
be to capture profitable export markets in Africa and 
beyond. So far, only South Africa’s largest manufacturer has 
had the vision and the capacity to execute a global 
expansion strategy successfully. For the remaining 
manufacturers success will most likely depend on how they 
embrace market opportunities with their current product 
portfolios and how they devise strategies to exploit other 
markets with large growth potentials. A comprehensive 
industrial strategy will have to be implemented after 
consultation with the entire local manufacturing industry in 





The changing structure of pharmaceutical manufacturing in 
South Africa can be characterised as an industry that 
previously had many manufacturing facilities operated by 
MNCs and a few local players. The global and local factors 
impacting on the industry had resulted in the largest local 
manufacturers playing more dominant roles within the local 
industry and the MNC manufacturers gradually decreasing 
their manufacturing presence locally. At the same time a 
few smaller local manufacturers have been able to remain 
viable by producing lower volumes of products destined for 
smaller niche local markets and in some cases export 
markets.  
 
On a broader policy level the DTI has realised the 
importance of this sector and it has been designated a 
priority sector in the IPAP in order to ensure that the 
industry remains viable and sustainable. Unfortunately, the 
DTI’s attempt at providing a pharmaceutical strategy is not 
met with tremendous support and strategic cohesion from 
the other government departments like the DOH and the 
Treasury. The pharmaceutical industry, in general, also 
appears reluctant to become involved in aiding the 
government in establishing a general strategy for the 
pharmaceutical sector. If a successful strategy is established 
for the pharmaceutical industry after joint consultation of all 
the stakeholders, it could mean that some manufacturers 
would invest locally or possibly re-invest locally provided 
that such an industrial strategy is able to offer sufficient 
incentives that make such investments attractive, address the 
skills shortages and reduce regulatory uncertainties.  
 
The international experience with new emerging 
multinational pharmaceutical companies demonstrates the 
importance of industry developing dynamic capabilities in 
response to exogenous shocks brought about by trade 
liberalisation. In South Africa these shocks have negatively 
affected production and resulted in reduced investment in 
new capabilities. The Indian case (Athreye et al., 2009; 
Chittoor et al., 2009) shows that dynamic capabilities can 
co-evolve with firm strategy in order to exploit new 
opportunities brought about by regulatory changes. The 
question for South Africa is whether the DTI’s recent 
industrial policies will act as a catalyst to the pharmaceutical 
industry not only to increase investment and production but 
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BEE Black Economic Empowerment 
 
cGMP Current Good Manufacturing Process/Practice 
 
DOH Department of Health 
DTI Department of Trade and Industry 
 
DST Department of Science and Technology 
 
FDA  Food and Drug Administration 
 
GMP Good Manufacturing Process/Practice 
 
IPRs Intellectual Property Rights 
 
IPAP Industrial Policy Action Plan 
 
M&A Mergers and Acquisitions 
 
PIASA Pharmaceutical Industry Association of South Africa 
 
PIC/S The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme 
(jointly referred to as “PIC/S”) 
 
R&D Research and Development  
 
SEP Single Exit Price 
 
TRIPS Trade-Related Aspects of Intellectual Property Rights 
 
WHO World Health Organization 
 





APPENDIX A: Research instrument 
 
1. What recent trends and changes in the global pharmaceutical industry have had an impact on local pharmaceutical 
production in general? 
 
2. How have the characteristics or behaviours of global multinational pharmaceutical companies affected the local 
pharmaceutical industry? 
 
3. How has global drug demand influenced the demand for locally manufactured pharmaceuticals and how has this 
influenced competition within the industry? 
 
4. How have global price controls affected the pharmaceutical production in South Africa? 
 
5. How have global patent protection and Intellectual Property Rights (IPRs) issues (e.g. parallel importing and 
compulsory licensing) influenced local pharmaceutical manufacturing? 
 
6. Which factors within South Africa have had the greatest impact on local pharmaceutical production? 
 
7. How have the characteristics or behaviours of local pharmaceutical companies affected the local pharmaceutical 
industry? 
 
8. How does the unavailability of locally manufactured inputs (e.g. active pharmaceutical ingredients and processing 
equipment) impact on local manufacturing? 
 
9. What government regulations, legislations or industrial policies have had an impact on manufacturing medicines in 
South Africa (e.g. DOH’s drug policy, MCC manufacturing licensing requirements, medicines registration, pricing 
policies or Industrial Policy Action Plans)?  
 
10. Is there a skills shortage within the industry and if so how does this affect the local manufacturing industry? 
 
11. What are the main implications of the changing structure in local pharmaceutical manufacturing and how has the local 
pharmaceutical manufacturing industry responded?  
 
12. What are the implications of the government’s regulations, legislations or industrial policies mentioned in section 2 and 
how has the pharmaceutical industry responded? 
 
13. How are local manufacturers adapting to changes within the local pharmaceutical industry? 
 
14. How have the volumes of locally produced drugs changed for this company or in general and what are the reasons for 
these changes? 
 
15. What is the future of pharmaceutical production in South Africa? 
 
APPENDIX B: List of interviewees 
 
No. Position Organisation 
1. CEO Merck Serono 
2. Senior Executive Aspen Pharmacare 
3. CEO IMSA 
4. CEO SAAPI 
5. Director: Technical Infrastructure Unit DTI 
6. CEO Mylan 
7. Director: 
Inspectorate and Law Enforcement 
MCC 
8. CEO Specpharm Holdings 
9. COO PIASA 
10. Senior Executive Cipla Medpro 
11. Supply Chain Executive Adcock Ingram  
12. CEO Columbia Pharmaceuticals 
13. General Manager  Merck Pharmaceutical Manufacturing 
 
